Dalton Pharma to Use Thermo Fisher Tech for Biopolymers | GenomeWeb
NEW YORK (GenomeWeb News) – Dalton Pharma Services will use Thermo Fisher Scientific’s enzyme-based technology to make nucleic acid biopolymers for use in drug development research projects, Toronto-base Dalton said today.
 
Dalton will produce poly-inosine and poly-cytosine in accordance with current good manufacturing practice regulations.
 
These polynucleotides are used as catalysts to stimulate immune responses when they are combined with other substances in a drug, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.